Aflibercept vs Surabgene lomparvovec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Surabgene lomparvovec

Developed by AbbVie and partners

Phase 3 in Age-Related Macular DegenerationAAV gene therapy
Weak signal

NCT04832724 · Phase 2 · completed

The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.

Next expected readout: December 2026 · NCT04704921 (registry estimate)

Reported efficacy

RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)

Result source: NCT04832724

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Aflibercept: 6 of 6 rows · Surabgene lomparvovec: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAflibercept
Rows use multiple source trials
Surabgene lomparvovec
CNV Area Change Mm2
absolute change · mm
No placebo or comparator arm
0.204 mm @ 52wk2 mg every 8 weeksa,b,c,d,e
NCT02540954 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.274 mm @ 52wk
NCT02540954 · Phase 3 · registry result, not featured evidence
-0.4 mm @ 106wka,b,c,d,e
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more doses
0 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.2 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-1.1 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-0.6 mm @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
CRT Change Microns
absolute change · m
No placebo or comparator arm
-134.4 m @ 52wka,f,c,d,e
NCT02305238 · Phase 4 · registry result, not featured evidence
show 1 more dose
-126.1 m @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
-88.6 m @ 106wka,f,c,d,e
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more doses
25.3 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-56.7 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-108.2 m @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Dropout rate
3.6%2.0mg Q4g
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
4.9%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%
NCT03022292 · Phase 4 · registry result, not featured evidence
6.1%
NCT02689518 · Phase 4 · registry result, not featured evidence
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
100%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
8.7%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
12.7%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
6.3%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.2%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
6.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
23.6%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
16.7%Cohort 1h
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
0%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
8.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
1%2.0mg Q4g
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
20%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
2.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
3.2%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—
NCT01950741 · Phase 4 · registry result, not featured evidence
—2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
2.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
3.2%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
—Cohort 1h
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
—Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
—Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Serious AEs
23%2.0mg Q4g
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
26.7%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
15.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
17.2%Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
2.1%
NCT01950741 · Phase 4 · registry result, not featured evidence
20%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
2.3%Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
5.7%Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
4.2%PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
45.9%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
33.3%Cohort 1h
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
33.3%Cohort 2
NCT03066258 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort 3
NCT03066258 · Phase 1/2 · registry result, not featured evidence
25%Cohort 4
NCT03066258 · Phase 1/2 · registry result, not featured evidence
33.3%Cohort 5
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
2.0mg Q4g
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 39 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
drop in visual acuity 7.7%
punctate epithelial erosion 7.7%
raised blood pressure 7.7%
NCT03117634 · Phase 4 · registry result, not featured evidence
drop in vision due to cataract 5.1%
drop in visual acuity 5.1%
peri-orbital oedema (extra-ocular) 2.6%
NCT03117634 · Phase 4 · registry result, not featured evidence
myelodysplastic syndrome 3.8%
pneumonia 3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
hypertension 13.3%
depression 6.7%
ocular hypertension 6.7%
NCT02120950 · Phase 4 · registry result, not featured evidence
viral upper respiratory tract infection 11.2%
hypertension 8.1%
dry eye 6.8%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
viral upper respiratory tract infection 15.9%
conjunctival haemorrhage 6.4%
vitreous floaters 5.7%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
conjunctival hemorrhage 8.5%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.0 mg
cataract progression 6.7%
geographic atrophy progression 6.7%
NCT01543568 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
conjunctival haemorrhage 6%
macular fibrosis 2.8%
retinal pigment epitheliopathy 2.8%
NCT01482910 · Phase 3 · registry result, not featured evidence
macular fibrosis 11.8%
visual acuity reduced 7%
conjunctival haemorrhage 6.1%
NCT01482910 · Phase 3 · registry result, not featured evidence
visual acuity reduced 7%
conjunctival haemorrhage 5.6%
intraocular pressure increased 1.4%
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
2mg
fall 18.5%
hypertension 16.6%
nasopharyngitis 16.6%
NCT00527423 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
h
intraocular inflammation 66.7%
retinal haemorrhage 66.7%
visual acuity reduced/impairment 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
conjunctival haemorrhage 50%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 66.7%
intraocular inflammation 50%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100%
conjunctival haemorrhage 75%
retinal thickening 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence
conjunctival haemorrhage 91.7%
retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7%
eye irritation 33.3%
NCT03066258 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 1/2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 106 weeks versus 52 weeks.
  6. fTrial phases differ: Phase 1/2 versus Phase 4.
  7. gPopulation comparability has not been reviewed for 39 of these studies.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
NEI VFQ-25 Total 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4
absolute change · score
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 5 more results
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 6.3 Ranibizumab score @ 52wk2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.9 vs 6.3 Ranibizumab score @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.1 vs 6.3 Ranibizumab score @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14 vs 3.9 PDT Letters correctly read @ 28wk
NCT01482910 · Phase 3 · registry result, not featured evidence
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 8.1 ETDRS Letters @ 52wk
absolute change · ETDRS Letters
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 ETDRS Letters @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
CST Change Microns -248.8 um @ 52wk
absolute change · um
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
-164.8 um @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
Complete Polyp Regression 53.8% (n=39) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 1 more result
38.5% (n=13) @ 52wk*
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
BCVA Letters 0.3 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.33 score @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
CST Change Microns 0.08 ratio @ 24wk
ratio to baseline · ratio
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.07 ratio @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence

+ 61 further endpoints in the CSV export.

Surabgene lomparvovec

BCVA Change Letters -7.6 ETDRS letters @ 106wk
absolute change · ETDRS letters
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
1.2 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
14 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
0.9 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
-3.8 ETDRS letters @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
Supplemental Injection Rate Annualized 10.3 per year @ 106wk
event rate · per year
No placebo or comparator arm
NCT03066258 · Phase 1/2 · registry result, not featured evidence
show 4 more results
9.3 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2.8 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
4.4 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence
2 per year @ 106wk
NCT03066258 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Surabgene lomparvovec's landscape